The phase 2 ACTIV-2 findings (NCT30318759), investigating camostat for Mild-Moderate COVID-19 were discussed in this short interview with Dr Nikolaus Jilg (Massachusetts General Hospital, Boston, MA, USA). Camostat is a serine protease inhibitor, and prevents activation of the SARS-CoV-2 spike protein and blocks SARS-CoV-2 infection in vitro. Dr Jilg and colleagues studied the safety and antiviral and clinical efficacy of orally administered camostat in non-hospitalized adults with mild-moderate COVID-19.
The abstract entitled: ‘Camostat is not Effective for Mild-Moderate COVID-19 In A Phase II Trial of ACTIV-2’ (Abstract #105) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What was the rationale for the use of camostat in the treatment of adults with mild-moderate COVID-19? (0:12)
- Could you give us a brief overview of the ACTIV-2/A5401 clinical trial? (1:19)
- What were the findings in terms of camostat efficacy and safety? (3:18)
- Why do you think camostat failed to show antiviral or clinical efficacy? (4:18)
- What are the implications of these findings for the evaluation of future therapies for COVID-19? (6:47)
Disclosures: Nikolaus Jilg has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In COVID-19
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Christoph Boesecke: Impact of COVID-19 on the treatment of patients living with HIV
Key clinical highlights in HIV infection are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Christoph Boesecke (Infectious Diseases Specialist, Senior Lecturer, University of Bonn, Bonn, Germany). He discusses the delays caused by the COVID-19 pandemic and the impact that has had on the treatment of patients living with HIV. He also […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!